Support is requested for an integrated clinical-therapeutic and laboratory research program on GROWTH CONTROL OF MULTIPLE MYELOMA by a team of experienced investigators, most of whom have interacted closely for several years and have independent research support. The clinical Project I emphasizes a curative approach for newly diagnosed patients through dose-intensive cytotoxic chemotherapy requiring hemopoietic growth factor and stem cell support (""""""""Total Therapy""""""""). In addition, biological agents with the potential of exerting direct antitumor effect or activating and augmenting normal host-defense mechanisms (T and NK cells) will be evaluated in previously treated patients. In order to take advantage of the large patient population seen at our Center with this rare malignancy and related disorders, a comprehensive workup will be performed of cytogenetics, molecular genetics and cytokines. the derived Myeloma Data Base should prove useful for a deeper understanding of etiology, disease manifestations and progression. the clinical project and the associated Cores (Chromosome and Molecular Genetics; Cytokines; Data Management) will provide a cohesive framework for specific basic laboratory research projects examining the intricate cytokine network involved in myeloma growth and clinical symptoms manifestation (Project II); the molecular mechanisms of dexamethasone activity and resistance (Project III); as well as the growth-controlling contributions of autoreactive cells shedding immunoglobulin binding factor (CD16) (Project IV). These host cells may be subject to therapeutic manipulations by biological events investigated in Project I, mainly dexamethasone, IL-4, ivIg, interferons and all-trans-retinoic acid.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-02
Application #
2096929
Study Section
Special Emphasis Panel (SRC (K2))
Project Start
1993-02-15
Project End
1996-01-31
Budget Start
1994-02-01
Budget End
1995-01-31
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Rasche, L; Alapat, D; Kumar, M et al. (2018) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia :
Went, Molly; Sud, Amit; Försti, Asta et al. (2018) Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 9:3707
Mehdi, Syed J; Johnson, Sarah K; Epstein, Joshua et al. (2018) Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol :
Rasche, Leo; Angtuaco, Edgardo J; Alpe, Terri L et al. (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132:59-66
Mohan, Meera; Samant, Rohan S; Yoon, Donghoon et al. (2017) Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res 32:1261-1266
Sawyer, J R; Tian, E; Shaughnessy Jr, J D et al. (2017) Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 31:637-644
Rasche, Leo; Angtuaco, Edgardo; McDonald, James E et al. (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30-34
Mikulasova, Aneta; Wardell, Christopher P; Murison, Alexander et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617-1625
Stein, Caleb K; Pawlyn, Charlotte; Chavan, Shweta et al. (2017) The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8:27854-27867
Chavan, S S; He, J; Tytarenko, R et al. (2017) Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 7:e535

Showing the most recent 10 out of 290 publications